Literature DB >> 1321339

A viral long terminal repeat expressed in CD4+CD8+ precursors is downregulated in mature peripheral CD4-CD8+ or CD4+CD8- T cells.

Y Paquette1, L Doyon, A Laperrière, Z Hanna, J Ball, R P Sekaly, P Jolicoeur.   

Abstract

The long terminal repeat from a thymotropic mouse mammary tumor virus variant, DMBA-LV, was used to drive the expression of two reporter genes, murine c-myc and human CD4, in transgenic mice. Expression was observed specifically in thymic immature cells. Expression of c-myc in these cells induced oligoclonal CD4+ CD8+ T-cell thymomas. Expression of human CD4 was restricted to thymic progenitor CD4- CD8- and CD4+ CD8+ T cells and was shut off in mature CD4+ CD8- and CD4- CD8+ T cells, known to be derived from the progenitor double-positive T cells. These results suggest the existence of similar and common factors in CD4+ CD8- and CD4- CD8+ T cells and support a model of differentiation of CD4+ CD8+ T cells through common signal(s) involved in turning off the expression of the CD4 or CD8 gene.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1321339      PMCID： PMC364609          DOI： 10.1128/mcb.12.8.3522-3530.1992

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN： 0270-7306            Impact factor:   4.272


  46 in total

Review 1.  Molecular mechanisms for lineage commitment in T cell development.

Authors:  E A Robey; B J Fowlkes; D M Pardoll
Journal:  Semin Immunol       Date:  1990-01       Impact factor: 11.130

2.  The major histocompatibility complex-restricted antigen receptor on T cells: distribution on thymus and peripheral T cells.

Authors:  N Roehm; L Herron; J Cambier; D DiGuisto; K Haskins; J Kappler; P Marrack
Journal:  Cell       Date:  1984-09       Impact factor: 41.582

3.  A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity.

Authors:  A P Feinberg; B Vogelstein
Journal:  Anal Biochem       Date:  1983-07-01       Impact factor: 3.365

4.  A superantigen encoded in the open reading frame of the 3' long terminal repeat of mouse mammary tumour virus.

Authors:  Y Choi; J W Kappler; P Marrack
Journal:  Nature       Date:  1991-03-21       Impact factor: 49.962

5.  Clonal deletion of V beta 14-bearing T cells in mice transgenic for mammary tumour virus.

Authors:  H Acha-Orbea; A N Shakhov; L Scarpellino; E Kolb; V Müller; A Vessaz-Shaw; R Fuchs; K Blöchlinger; P Rollini; J Billotte
Journal:  Nature       Date:  1991-03-21       Impact factor: 49.962

6.  The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice.

Authors:  J M Adams; A W Harris; C A Pinkert; L M Corcoran; W S Alexander; S Cory; R D Palmiter; R L Brinster
Journal:  Nature       Date:  1985 Dec 12-18       Impact factor: 49.962

7.  A 3' end fragment encompassing the transcriptional enhancers of nondefective Friend virus confers erythroleukemogenicity on Moloney leukemia virus.

Authors:  P A Chatis; C A Holland; J E Silver; T N Frederickson; N Hopkins; J W Hartley
Journal:  J Virol       Date:  1984-10       Impact factor: 5.103

8.  Rearrangement of a DNA sequence homologous to a cell-virus junction fragment in several Moloney murine leukemia virus-induced rat thymomas.

Authors:  G Lemay; P Jolicoeur
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

9.  Organization and reorganization of immunoglobulin genes in A-MULV-transformed cells: rearrangement of heavy but not light chain genes.

Authors:  F Alt; N Rosenberg; S Lewis; E Thomas; D Baltimore
Journal:  Cell       Date:  1981-12       Impact factor: 41.582

10.  Thymotropism of murine leukemia virus is conferred by its long terminal repeat.

Authors:  L DesGroseillers; E Rassart; P Jolicoeur
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205
View more
  9 in total

1.  The c-myc locus is a common integration site in type B retrovirus-induced T-cell lymphomas.

Authors:  L Rajan; D Broussard; M Lozano; C G Lee; C A Kozak; J P Dudley
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

2.  Studies of the susceptibility of nude, CD4 knockout, and SCID mutant mice to the disease induced by the murine AIDS defective virus.

Authors:  C Simard; S J Klein; T Mak; P Jolicoeur
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

3.  Identification of Notch1 as a frequent target for provirus insertional mutagenesis in T-cell lymphomas induced by leukemogenic mutants of mouse mammary tumor virus.

Authors:  S Yanagawa; J S Lee; K Kakimi; Y Matsuda; T Honjo; A Ishimoto
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

4.  Selection for c-myc integration sites in polyclonal T-cell lymphomas.

Authors:  Dana R Broussard; Jennifer A Mertz; M Lozano; Jaquelin P Dudley
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

5.  Murine AIDS is initiated in the lymph nodes draining the site of inoculation, and the infected B cells influence T cells located at distance, in noninfected organs.

Authors:  C Simard; M Huang; P Jolicoeur
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

6.  Type B leukemogenic virus has a T-cell-specific enhancer that binds AML-1.

Authors:  J A Mertz; F Mustafa; S Meyers; J P Dudley
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

7.  Evidence that the murine AIDS defective virus does not encode a superantigen.

Authors:  L Doyon; C Simard; R P Sékaly; P Jolicoeur
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

8.  Specific expression of the human CD4 gene in mature CD4+ CD8- and immature CD4+ CD8+ T cells and in macrophages of transgenic mice.

Authors:  Z Hanna; C Simard; A Laperrière; P Jolicoeur
Journal:  Mol Cell Biol       Date:  1994-02       Impact factor: 4.272

9.  Ahi-1, a novel gene encoding a modular protein with WD40-repeat and SH3 domains, is targeted by the Ahi-1 and Mis-2 provirus integrations.

Authors:  Xiaoyan Jiang; Zaher Hanna; Mohammadi Kaouass; Luc Girard; Paul Jolicoeur
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.